Free shipping on all orders over $ 500

0 item(s) - SubTotal: $0
Shipping Fee: $40

View cart   Checkout

  Catalog
abmole catalog
Related VEGFR/PDGFR Inhibitors
PP121

PP121 is a dual inhibitor of tyrosine and phosphoinositide kinases.

DMXAA

DMXAA (Vadimezan, ASA404) is a tumor-vascular disrupting agent (tumor-VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM, respectively.

Ki8751

Ki8751 is a potent, selective inhibitor of VEGFR-2 tyrosine kinase (IC50 = 0.9 nM).

SU5416

Cat. No. M2031

SU5416 Structure

Synonym: Semaxanib

Size Price Availability Quantity
10mg $100 In stock
50mg $200 In stock
100mg $300 In stock
Bulk Inquiry?

Quality Control

  • Current batch:
  • Purity >98%
  • COA
  • MSDS

Biological Activity

SU5416 (Semaxanib) is a potent and selective vascular endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2 inhibitor that also inhibits other tyrosine kinases KIT, MET, FLT3 and RET. SU5416 inhibited cell migration of human vascular endothelial cells expressing both Flt-1 and KDR in response to VEGF and also inhibited the cell migration in response to placenta growth factor (PIGF), a specific ligand for Flt-1. Chemotaxis of monocytes expressing only Flt-1 was also inhibited by SU5416 in a dose-dependent manner. Moreover, SU5416 was found to inhibit tyrosine kinase of Flt-1 in response to PIGF in vitro. SU5416 efficiently inhibited Kit activity in vivo when administered on a twice-weekly schedule.


Chemical Information

Molecular Weight 238.28
Formula C15H14N2O
CAS Number 204005-46-9
Purity >98%
Solubility DMSO
Storage at -20°C

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
O'Donnell A, et al. Br J Cancer. 2005 Oct 17;93(8):876-83. PMID: 16222321.

Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.
Itokawa T, et al. Mol Cancer Ther. 2002 Mar;1(5):295-302. PMID: 12489845.

The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Mendel DB, et al. Clin Cancer Res. 2000 Dec;6(12):4848-58. PMID: 11156244.

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
Fong TA, et al. Cancer Res. 1999 Jan 1;59(1):99-106. PMID: 9892193.



Keywords: SU5416, Semaxanib, supplier, potent, VEGFR/PDGFR, kinases, inhibitors, inhibits

Sign up for our weekly newsletter and stay up-to-date with the latest offers, and newest products!

Get free sample